Peregrine Capital Management’s Cytokinetics CYTK Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.83M	Sell	103,626 -4,436	-4%	-$282K	0.25%	118
2025 Q4	$6.87M	Sell	108,062 -46,387	-30%	-$2.89M	0.21%	136
2025 Q3	$8.49M	Sell	154,449 -4,079	-3%	-$168K	0.26%	106
2025 Q2	$5.24M	Buy	158,528 +2,791	+2%	+$97.1K	0.16%	192
2025 Q1	$6.26M	Buy	155,737 +5,394	+4%	+$248K	0.21%	144
2024 Q4	$7.07M	Buy	150,343 +9,432	+7%	+$490K	0.21%	135
2024 Q3	$7.44M	Buy	140,911 +310	+0.2%	+$17.3K	0.22%	118
2024 Q2	$7.62M	Buy	140,601 +14,208	+11%	+$858K	0.22%	141
2024 Q1	$8.86M	Sell	126,393 -5,121	-4%	-$396K	0.25%	105
2023 Q4	$11M	Sell	131,514 -73,150	-36%	-$2.65M	0.33%	60
2023 Q3	$6.03M	Buy	204,664 +23,936	+13%	+$797K	0.18%	219
2023 Q2	$5.9M	Sell	180,728 -18,688	-9%	-$691K	0.16%	232
2023 Q1	$7.02M	Buy	199,416 +39,273	+25%	+$1.6M	0.2%	216
2022 Q4	$7.34M	Buy	160,143 +11,309	+8%	+$487K	0.23%	202
2022 Q3	$7.21M	Sell	148,834 -25,659	-15%	-$1.23M	0.23%	200
2022 Q2	$6.86M	Sell	174,493 -45,047	-21%	-$1.81M	0.21%	217
2022 Q1	$8.08M	Buy	219,540 +3,160	+1%	+$112K	0.19%	217
2021 Q4	$9.86M	Sell	216,380 -72,116	-25%	-$2.78M	0.2%	203
2021 Q3	$10.3M	Sell	288,496 -135,679	-32%	-$3.99M	0.21%	205
2021 Q2	$8.39M	Sell	424,175 -22,379	-5%	-$525K	0.15%	246
2021 Q1	$10.4M	Sell	446,554 -109,130	-20%	-$2.33M	0.19%	228
2020 Q4	$11.5M	Buy	+555,684	New	+$10.2M	0.22%	214